SK bioscience, an innovative vaccine and biotech company committed to promoting human health from prevention to cure, announced that the company has signed a Memorandum of Understanding (MOU) with the Government Pharmaceutical Organization (GPO), a state pharmaceutical enterprise in Thailand, to strengthen Thailand's vaccine infrastructure.
The purpose of the MOU is to strengthen the responding system against new pandemics and localize Thailand's vaccine manufacturing capabilities which will extend to the broader Southeast Asia.
The GPO is a state-owned pharmaceutical company established in 1966, supplying medicines and vaccines in Thailand. Thailand's public hospitals use at least 60% of mandatory GPO products, including pharmaceuticals and medical devices.
Through the MOU, SK bioscience and the GPO will strengthen Thailand's vaccine development and manufacturing capabilities and collaborate closely in the mid- to long-term to support Thailand becoming a vaccine hub in Southeast Asia.
As a first step of the MOU, SK bioscience and the GPO also plan to sign the agreement which transfers drug product manufacturing technology of cell culture-based influenza vaccine developed by SK bioscience for local manufacturing at the plant owned by the GPO.
Once the technology transfer is completed, the GPO will receive drug substance of the influenza vaccine from SK bioscience and plan to obtain a marketing authorization from the regulatory health agency. Both organizations expect that the influenza vaccine manufactured by the GPO will be utilized for the Thailand's national immunization program.
In the long term, SK bioscience plans to transfer its manufacturing capability and expand supplying self-developed vaccines in other Southeast Asian countries. SK bioscience will collaborate with the GPO, the essential partner in supplying medicines in Thailand and further contribute to promoting public health in Southeast Asia.
Comments powered by CComment